Recursion Pharmaceuticals Stock Performance
| RXRX Stock | USD 4.55 0.18 4.12% |
The company holds a Beta of 3.23, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Recursion Pharmaceuticals will likely underperform. At this point, Recursion Pharmaceuticals has a negative expected return of -0.29%. Please make sure to check Recursion Pharmaceuticals' information ratio, skewness, day typical price, as well as the relationship between the treynor ratio and daily balance of power , to decide if Recursion Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Recursion Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 4.12 | Five Day Return 9.11 | Year To Date Return 8.33 | Ten Year Return (74.72) | All Time Return (74.72) |
1 | Disposition of 100000 shares by Christopher Gibson of Recursion Pharmaceuticals at 5.7 subject to Rule 16b-3 | 10/23/2025 |
2 | Recursion Pharmaceuticals Reports Q3 Loss, Misses Revenue Estimates | 11/05/2025 |
3 | Disposition of 40390 shares by Christopher Gibson of Recursion Pharmaceuticals at 4.14 subject to Rule 16b-3 | 11/17/2025 |
4 | Is Recursion Pharmaceuticals a Meme Stock | 11/19/2025 |
5 | Disposition of 2271 shares by Ben Taylor of Recursion Pharmaceuticals at 4.03 subject to Rule 16b-3 | 11/25/2025 |
6 | Disposition of 220000 shares by Blake Borgeson of Recursion Pharmaceuticals at 4.37 subject to Rule 16b-3 | 12/02/2025 |
7 | Recursion Pharmaceuticals Shares Gap Up Heres What Happened | 12/08/2025 |
8 | Disposition of 7057 shares by Ben Taylor of Recursion Pharmaceuticals at 4.33 subject to Rule 16b-3 | 12/15/2025 |
9 | Recursion Pharmaceuticals Nasdaq Index Fund Spotlight | 12/17/2025 |
10 | What Recursion Pharmaceuticals s FAP Trial Win And AI Platform Validation Means For Shareholders | 12/18/2025 |
11 | Cathie Wood Keeps Dumping Tesla Stock -- Here is Why | 12/19/2025 |
12 | Disposition of 124403 shares by Najat Khan of Recursion Pharmaceuticals at 4.4098 subject to Rule 16b-3 | 12/22/2025 |
13 | Recursion Pharmaceuticals Reports Positive Phase 1b2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP | 12/29/2025 |
14 | Cathie Woods ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. | 12/31/2025 |
15 | JPMorgan Boosts Rating on Recursion Pharmaceuticals Amid AI-Driven Drug Pipeline | 01/02/2026 |
16 | Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference | 01/06/2026 |
| Begin Period Cash Flow | 401.4 M | |
| Total Cashflows From Investing Activities | 260.1 M |
Recursion | Build AI portfolio with Recursion Stock |
Recursion Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 591.00 in Recursion Pharmaceuticals on October 9, 2025 and sell it today you would lose (136.00) from holding Recursion Pharmaceuticals or give up 23.01% of portfolio value over 90 days. Recursion Pharmaceuticals is currently does not generate positive expected returns and assumes 5.3245% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Recursion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Recursion Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Recursion Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Recursion Pharmaceuticals, and traders can use it to determine the average amount a Recursion Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0547
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RXRX |
Based on monthly moving average Recursion Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Recursion Pharmaceuticals by adding Recursion Pharmaceuticals to a well-diversified portfolio.
Recursion Pharmaceuticals Fundamentals Growth
Recursion Stock prices reflect investors' perceptions of the future prospects and financial health of Recursion Pharmaceuticals, and Recursion Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Recursion Stock performance.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (33.28) % | ||||
| Current Valuation | 1.61 B | ||||
| Shares Outstanding | 514.19 M | ||||
| Price To Book | 2.09 X | ||||
| Price To Sales | 52.14 X | ||||
| Revenue | 58.84 M | ||||
| Gross Profit | (503.45 M) | ||||
| EBITDA | (426.72 M) | ||||
| Net Income | (463.66 M) | ||||
| Cash And Equivalents | 515.44 M | ||||
| Cash Per Share | 2.98 X | ||||
| Total Debt | 108.49 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 5.65 X | ||||
| Book Value Per Share | 2.13 X | ||||
| Cash Flow From Operations | (359.17 M) | ||||
| Earnings Per Share | (1.84) X | ||||
| Market Capitalization | 2.28 B | ||||
| Total Asset | 1.45 B | ||||
| Retained Earnings | (1.43 B) | ||||
| Working Capital | 526.8 M | ||||
About Recursion Pharmaceuticals Performance
Evaluating Recursion Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Recursion Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Recursion Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 11.13 | 10.57 | |
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.52) | (0.49) |
Things to note about Recursion Pharmaceuticals performance evaluation
Checking the ongoing alerts about Recursion Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Recursion Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Recursion Pharmaceuticals generated a negative expected return over the last 90 days | |
| Recursion Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 58.84 M. Net Loss for the year was (463.66 M) with loss before overhead, payroll, taxes, and interest of (503.45 M). | |
| Recursion Pharmaceuticals currently holds about 515.44 M in cash with (359.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98. | |
| Recursion Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference |
- Analyzing Recursion Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Recursion Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Recursion Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Recursion Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Recursion Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Recursion Pharmaceuticals' stock. These opinions can provide insight into Recursion Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.